A retrospective, observational study of dulaglutide and other GLP-1 receptor agonist in patients with type 2 diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 May 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 May 2017 Results assessing diabetes-related resource utilization and costs over the same 6-month post-index period intType 2 diabetes treated with Dulaglutide vs. Exenatide Qw or Liraglutide, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
16 Sep 2016 Results (n=4451) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
30 May 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com